The overall objectives of the JTC2025 will be to 

• Support research projects in human health on pharmacogenomic strategies for personalised medicine approaches that address one or more of the following aspects: 
  • Identification of new pharmacogenomic markers or signatures using (multi)-omics data in relation to drug or drug combination. 
  • Validation of a pharmacogenomic marker or signatures using (multi)-omics data in predicting drug or drug combination outcomes. 
  • Use pharmaco-omics strategies to determine the right dosage, the efficacy of treatments and/or the risk of adverse drug response and non-response to treatment to tailor personalised treatment pathways, including combined treatments (multi-medication). 
• Encourage and enable interdisciplinary collaborations, i.e. multi-actor research by engaging a range of other relevant disciplines such as pre-clinical and clinical research, bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to support the implementation of the research outcomes into clinical practice. 

• Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises), industry, as well as regulatory/HTA agencies and patient organisations. 

• Establish participatory research, i.e. active representation of patients or citizens as part of research projects. 

Projects are encouraged to combine the following aspects in their research: 

1. Omics data such as epigenomics, transcriptomics, proteomics and metabolomics data in addition to genomics data in relation to treatment outcomes. A key goal is to assess the importance of one or more -omics approaches (multi-modal approaches) in optimising treatment outcomes. 
2. Information regarding patient medication (prescription and non-prescription), dose or compliance.  
3. Information (including clinical and environmental factors) regarding medication efficacy, adverse effects and patient reported outcomes (PRO). 

Participatory research should be established in that active representation of patients or citizens is part of research projects. EP PerMed is supporting this approach by providing dedicated funding to organisations representing patients or citizens to participate as partners in proposals submitted to this call. Those organisations could support in designing the research, ensuring that research questions are relevant from the patients’ and citizens’ point of view. They might also support in collecting data for PROs and adverse effects.  

Projects funded under this call are furthermore required to include a dedicated work package focussing on the question of implementation of the research outcomes into clinical practice with a focus on e.g. patient outcome, costs, reimbursement, education, ELSA (ethical, legal and societal aspect) or feasible use at the point of care.  

Research projects in all disease areas are welcome. Research on polygenic drug response phenotypes is encouraged. 

Exclusion: Projects focussing only on drug-drug-interaction are out of scope. Projects focusing on the clinical development of new drugs are out scope. 

Please note clinical trials and investigations are not eligible for funding by Research Ireland for the Irish-based applicant. Where clinical studies are proposed within the workplan of a proposal, study sites and the delineation of activities among proposal partners should be made clear. 

• Applicants must meet the primary eligibility and consortium requirements of JTC2025 and  

• Research Ireland’s eligibility requirements specified for Irish-based applicants. Please refer to Pg 52-54 of the Applicant guidance document. 

• Research Ireland’s Who Can Apply policy document available here.  

In addition: 

• Research Ireland will only accept one application per applicant. 

Awarded projects will have a duration of up to 36 months. For applicants based in Ireland, Research Ireland will provide the following funding for projects:  

• Up to a maximum of €330,000 direct costs* per award for Irish applicants as Partner on transnational proposals.  

• Up to a maximum of €405,000 direct costs* per award for Irish applicants as Coordinator on transnational proposals.  

*The maximum total award, including overhead contribution, will be €430,000, for a partner and €530,000 for applicants who take on the role of coordinator. 

Please give a brief notification of your intent to submit a pre-proposal through email to eu-cofund@researchireland.ie before the submission deadline. Within the notification, please include the following information:   

• List of project partners  

• Irish Host institution*   

• Total budget request to Research Ireland  

• Whether you intend to apply as a coordinating or non-coordinating partner  

 *Please note it is also the responsibility of the applicant to notify the Research Office of their Host Institution of their intention to submit a pre-proposal. 

The completed pre-proposal must be submitted directly on the EP PerMed submission platform.

The call text and all additional documents can be downloaded below:

Call text (PDF)

Guidelines for applicants (PDF)

Pre-proposal form (DOCX)

Research Ireland EP PerMed JTC2025 FAQ

• 16 December, 2024: Publication of the call
• 09 January 2025: JTC2025 information day
• 18 February, 2025 (14:00, CET): Deadline for pre-proposal submission
• Expected around 15 May, 2025: Communication of the results of the pre-proposal assessment and invitation to the full-proposal stage
• 17 June, 2025 (14:00, CEST): Deadline for full-proposal submission
• Mid/end of August 2025: Rebuttal stage
• Expected for October 2025: Communication of the funding decisions to the applicants
• End of 2025, beginning of 2026: Expected project start (according to regional/national funding regulations)